-

LINC CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Lincoln Educational Services Corporation Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Bacha v. Lincoln Educational Services Corporation, et al., Case No. 2:26-cv-11842, on behalf of persons and entities that purchased or otherwise acquired Lincoln Educational Services Corporation (“Lincoln” or the “Company”) (NASDAQ: LINC) securities between May 11, 2026 and August 9, 2026, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.

IF YOU SUFFERED A LOSS ON YOUR LINCOLN EDUCATIONAL SERVICES CORPORATION INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?

On August 10, 2026, before the market opened, Lincoln reported earnings for the second quarter of 2026. Among other things, the Company reported student starts increased by only 1% year over year despite enrollment growing 9%, “as fewer enrolled students than expected attended the first day of class.” The Company further disclosed that “during the quarter, we observed changes in the student decision-making process that affected conversion from enrollment to start” and that Lincoln “ha[s] taken, and [will] continue to take, actions to address these trends . . . .”

On this news, Lincoln’s stock price fell $10.22 or 24.93% to close at $30.77 on August 10, 2026, thereby injuring investors

What Is the Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) that the Company’s admissions process was not effectively converting students from enrollment to start; (2) that, as a result, the Company was experiencing a significant drop in student starts relative to enrollment; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired Lincoln Educational Services Corporation securities during the Class Period, you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff.

Contact Us to Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Charles H. Linehan, Esq.
Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles H. Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Glancy Prongay Wolke & Rotter LLP

NASDAQ:LINC

Release Versions

Contacts

Glancy Prongay Wolke & Rotter LLP
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles H. Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

More News From Glancy Prongay Wolke & Rotter LLP

Securities Fraud Class Action Filed Against D-Wave Quantum, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

LOS ANGELES--(BUSINESS WIRE)--A securities fraud class action lawsuit has been filed against D-Wave Quantum, Inc. ("D-Wave" or the "Company") (NASDAQ: QBTS) on behalf of investors who purchased or otherwise acquired the Company's securities between February 26, 2026 and August 25, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced the filing. The D-Wave Quantum, Inc. case, Fessler v. D-Wave Quantum, Inc. et al., was filed on October 15, 2026 in the U.S. District C...

Deadline Alert: Bank Of America Corporation Investors Have Until December 15, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

LOS ANGELES--(BUSINESS WIRE)--Investors in Bank Of America Corporation ("Bank of America" or the "Company") (NYSE: BAC) have until December 15, 2026 to ask the Court to appoint them lead plaintiff in a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Bank Of America Corporation securities between August 1, 2025 and October 13, 2026, inclusive. Glancy Prongay Wolke & Rotter LLP ("Glancy") today reminded investors of the upcoming deadline....

Lost Money on Moderna, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 23.07% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.Investors who lost money on Moderna, Inc. securit...
Back to Newsroom